

Tumor Volume (mm3)
3000
2000
1000
0
0
10
20
30
Days
Vehicle 2Q7Dx4
Anti-PD-1 200 µg Q3Dx35
Compound 1 75 mg/kg 2Q7Dx6
Compound 1 150 mg/kg 2Q7Dx15
Compound 1 75 mg/kg 2Q7Dx15 + Anti-PD-1 Q3Dx35
Compound 1 150 mg/kg 2Q7Dx15 + Anti-PD-1 Q3Dx35

FIG. 1



Tumor Volume (mm3)
3000
2000
1000
0
-1000
50
100
150
200
Days
Vehicle 2Q7Dx4
Anti-PD-1 200 µg Q3Dx35
Compound 1 75 mg/kg 2Q7Dx6
Compound 1 150 mg/kg 2Q7Dx15
Compound 1 75 mg/kg 2Q7Dx15 + Anti-PD-1 Q3Dx35
Compound 1 150 mg/kg 2Q7Dx15 + Anti-PD-1 Q3Dx35

FIG. 2



Controls
Compound 1
Cpd 1 + PD1
Vehicle
Anti-PD-1, 200ug Q3D
2 cures
Compound 1, 75 mg/kg 2Q7D
57% TGI D20
Compound 1, 150 mg/kg 2Q7D
96% TGI D20
1 cures
Compound 1, 75 mg/kg + Anti-PD-1
3 cures
Compound 1, 150 mg/kg + Anti-PD-1
5 cures
Tumor Volume (mm3)
Days
mouse 1
mouse 2
mouse 3
mouse 4
mouse 5
mouse 6
mouse 7
mouse 8
mouse 9
mouse 10

FIG. 3



100
50
0
Percent survival (%)
0
50
100
150
200
*
Days Post Implant
Vehicle
PD-1
75 mg/kg
150 mg/kg
75 + PD-1
150 + PD-1
*Treatment discontinued day 102

FIG. 4



Percent Body Weight Change (%)
80
60
40
20
0
-20
50
100
150
200
Days
Vehicle 2Q7Dx4
Anti-PD-1 200 µg Q3Dx35
Compound 1 75 mg/kg 2Q7Dx6
Compound 1 150 mg/kg 2Q7Dx15
Compound 1 75 mg/kg 2Q7Dx15 + Anti-PD-1 200 µg Q3Dx35
Compound 1 150 mg/kg 2Q7Dx15 + Anti-PD-1 200 µg Q3Dx35

FIG. 5



Tumor Volume (mm3)
3000
2000
1000
0
0
5
10
15
20
25
Days Post Implant
Vehicle Q7Dx3
Anti-PD-1 200 µg Q3Dx19
Compound 1 150 mg/kg Q7Dx5
Compound 1 300 mg/kg Q7Dx9
Compound 1 600 mg/kg Q7Dx9
Compound 1 150 mg/kg Q7Dx9 + Anti-PD-1 200 µg Q3Dx19
Compound 1 300 mg/kg Q7Dx9 + Anti-PD-1 200 µg Q3Dx19

FIG. 6



Tumor Volume (mm3)
3000
2500
2000
1500
1000
500
0
-500
25
50
75
100
125
150
175
Days Post Implant
Vehicle Q7Dx3
Anti-PD-1 200 µg Q3Dx19
Compound 1 150 mg/kg Q7Dx5
Compound 1 300 mg/kg Q7Dx9
Compound 1 600 mg/kg Q7Dx9
Compound 1 150 mg/kg Q7Dx9 + Anti-PD-1 200 µg Q3Dx19
Compound 1 300 mg/kg Q7Dx9 + Anti-PD-1 200 µg Q3Dx19

FIG. 7



Vehicle Q7Dx3
Anti-PD-1 200 µg Q3Dx19
Compound 1 600 mg/kg Q7Dx9
Compound 1 150 mg/kg Q7Dx5
Compound 1 300 mg/kg Q7Dx9
Compound 1 150 mg/kg Q7Dx9
Anti-PD-1200 µg Q3Dx19
Compound 1 300 mg/kg Q7Dx9
Anti-PD-1200 µg Q3Dx19
Tumor Volume (mm3)
Days

FIG. 8

FIG. 8



120
100
80
60
40
20
0
Percent survival (%)
0
25
50
75
100
125
150
175
Days Post Implant
Vehicle Q7Dx3
Anti-PD-1 200 µg Q3Dx19
Compound 1 150 mg/kg Q7Dx5
Compound 1 300 mg/kg Q7Dx9
Compound 1 600 mg/kg Q7Dx9
Compound 1 150 mg/kg Q7Dx9 + Anti-PD-1 200 µg Q3Dx19
Compound 1 300 mg/kg Q7Dx9 + Anti-PD-1 200 µg Q3Dx19

FIG. 9



Percent Body Weight Change (%)
50
40
30
20
10
0
-10
50
100
150
Days
Vehicle Q7Dx3
Anti-PD-1 200 µg Q3Dx19
Compound 1 150 mg/kg Q7Dx5
Compound 1 300 mg/kg Q7Dx9
Compound 1 600 mg/kg Q7Dx9
Compound 1 150 mg/kg Q7Dx9 + Anti-PD-1 200 µg Q3Dx19
Compound 1 300 mg/kg Q7Dx9 + Anti-PD-1 200 µg Q3Dx19

FIG. 10



Tumor Volume (mm3)
4000
3000
2000
1000
0
0
10
20
30
40
Days
Vehicle
Compound 1 150 mg/kg Q7Dx2
Compound 1 300 mg/kg Q7Dx2
Compound 1 600 mg/kg Q7Dx2

FIG. 11



Tumor Volume (mm3)
3500
3000
2500
2000
1500
1000
500
0
0
5
10
15
20
25
Days
Vehicle 2Q7Dx4
Anti-PD-1 200 µg Q3Dx7
Compound 2 50 mg/kg QDx44
Compound 2 100 mg/kg QDx71
Compound 2 150 mg/kg 2Q7Dx10
Compound 2 300 mg/kg 2Q7Dx11
Compound 2 50 mg/kg QDx71
+ Anti-PD-1 200 µg Q3Dx24
Compound 2 150 mg/kg 2Q7Dx11
+ Anti-PD-1 200 µg Q3Dx24

FIG. 12



Vehicle 2Q7Dx4
Anti-PD-1 200 µg Q3Dx7
Compound 2 50 mg/kg QDx44
Compound 2 100 mg/kg QDx71
Compound 2 150 mg/kg 2Q7Dx10
Compound 2 300 mg/kg 2Q7Dx11
Compound 2 50 mg/kg QDx71 + Anti-PD-1 200 µg Q3Dx24
Compound 2 150 mg/kg 2Q7Dx11 + Anti-PD-1 200 µg Q3Dx24
Tumor Volume (mm3)
4000
3000
2000
1000
0
0
50
100
150
200
Days

FIG. 13



Vehicle 2Q7Dx4
Anti-PD-1 200 ug Q3Dx7
Compound 2 50 mg/kg QDx44
Compound 2 100 mg/kg QDx71
Compound 2 150 mg/kg 2Q7Dx10
Compound 2 300 mg/kg 2Q7Dx11
Compound 2 50 mg/kg QDx71
+ Anti-PD1 200 µg Q3Dx24
Compound 2 150 mg/kg 2Q7Dx11
+ Anti-PD1 200 µg
Tumor Volume (mm³)
Days
Mouse 1
Mouse 2
Mouse 3
Mouse 4
Mouse 5
Mouse 6
Mouse 7
Mouse 8
Mouse 9
Mouse 10

FIG. 14



Percent survival (%)
100
50
0
0
50
100
150
Days Post Implant
Vehicle 2Q7Dx4
Anti-PD-1 200 µg Q3Dx7
Compound 2 50 mg/kg QDx44
Compound 2 100 mg/kg QDx71
Compound 2 150 mg/kg 2Q7Dx10
Compound 2 300 mg/kg 2Q7Dx11
Compound 2 50 mg/kg QDx71
+ Anti-PD-1 200 µg Q3Dx24
Compound 2 150 mg/kg 2Q7Dx11
+ Anti-PD-1 200 µg Q3Dx24

FIG. 15



Percent survival (%)
100
50
0
0
50
*
100
150
Days Post Implant
Vehicle
Anti-PD-1
Compound 2 50 mg/kg QD
Compound 2 100 mg/kg QD
Compound 2 50 mg/kg QD + PD1
* Dosing Suspended Day 70

FIG. 16



Percent Body Weight Change (%)
60
40
20
0
-20
50
100
150
200
Days
Vehicle 2Q7Dx4
Anti-PD-1 200 µg Q3Dx7
Compound 2 50 mg/kg QDx44
Compound 2 100 mg/kg QDx71
Compound 2 150 mg/kg 2Q7Dx10
Compound 2 300 mg/kg 2Q7Dx11
Compound 2 50 mg/kg QDx71
+ Anti-PD-1 200 µg Q3Dx24
Compound 2 150 mg/kg 2Q7Dx11
+ Anti-PD-1 200 µg Q3Dx24

FIG. 17